TABLE 4.
Adjusted Overall Survival (n = 29,088)
| Variable | Death Rate = 6,901/29,088 (23.7%) | ||
|---|---|---|---|
| HR (95% CI) | P | Overall P | |
| Overall response | <.001 | ||
| RD | Ref | ||
| pCR | 0.25 (0.23 to 0.28) | <.001 | |
| Race/ethnicity | <.001 | ||
| NHW | Ref | ||
| Hispanic | 0.76 (0.69 to 0.85) | <.001 | |
| NHA | 0.64 (0.55 to 0.75) | <.001 | |
| NHB | 1.04 (0.98 to 1.1) | .23 | |
| Other | 0.93 (0.73 to 1.18) | .55 | |
| Age, years | <.001 | ||
| >50 | Ref | ||
| <50 | 0.89 (0.84 to 0.94) | <.001 | |
| Charlson/Deyo comorbidity score | <.001 | ||
| 0 | Ref | ||
| 1 | 1.17 (1.09 to 1.26) | <.001 | |
| ≥2 | 1.46 (1.28 to 1.66) | <.001 | |
| Income level | .04 | ||
| <$48,000 USD | Ref | ||
| ≥$48,000 USD | 0.94 (0.88 to 1) | .04 | |
| Insurance type | <.001 | ||
| Private | Ref | ||
| Government | 1.28 (1.21 to 1.35) | <.001 | |
| None | 1.14 (0.98 to 1.32) | .09 | |
| Grade | .01 | ||
| 1 | Ref | ||
| 2 | 1.31 (0.95 to 1.79) | .10 | |
| 3 | 1.41 (1.03 to 1.92) | .03 | |
| Clinical T-stage | <.001 | ||
| T1 | Ref | ||
| T0/IS | 1.51 (0.89 to 2.56) | .13 | |
| T2 | 1.28 (1.19 to 1.37) | <.001 | |
| T3 | 1.62 (1.49 to 1.77) | <.001 | |
| T4 | 2.09 (1.89 to 2.3) | <.001 | |
| Clinical N-stage | <.001 | ||
| N0 | Ref | ||
| N1 | 1.74 (1.64 to 1.85) | <.001 | |
| N2 | 2.16 (1.96 to 2.38) | <.001 | |
| N3 | 2.71 (2.46 to 3) | <.001 | |
NOTE. Model also adjusted for education level, facility type and location, community type, treatment with radiation, tumor size, surgery type, and weeks from diagnosis to surgery.
Abbreviations: HR, hazard ratio; IS, in situ; N, node; NHA, Non-Hispanic Asian; NHB, Non-Hispanic Black; NHW, Non-Hispanic White; pCR, pathologic complete response; RD, residual disease; ref, reference; T, tumor; USD, US dollars.